- Home
- GGT vs SLGL Comparison
GGT vs SLGL Comparison
Compare GGT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGT | SLGL |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.8M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GGT | SLGL |
|---|---|---|
| Price | $4.21 | $53.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 59.7K | 18.9K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.90 | ★ N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $4.32 | $4.02 |
| 52 Week High | $7.00 | $52.26 |
Technical Indicators
Market Signals| Indicator | GGT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 71.05 |
| Support Level | $4.11 | $40.10 |
| Resistance Level | $4.25 | $44.99 |
| Average True Range (ATR) | 0.07 | 3.02 |
| MACD | 0.00 | 0.51 |
| Stochastic Oscillator | 78.89 | 81.93 |
Price Performance
Historical ComparisonAbout GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.